



JFW

Patent Application
Attorney Docket No. PC10959B

I hereby certify that this correspondence is being deposited with the United States Postal Service as First class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 16th day of September, 2004.

By

Janice Denison
(Signature of person mailing)
Janice Denison
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark David Fidock :

APPLICATION NO.: 10/763,854 : Examiner: Li, Ruixiang

FILING DATE: 01/22/2004 : Group Art Unit: 1646

TITLE: NOVEL POLYPEPTIDE :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: September 16th, 2004

Respectfully submitted,




Deborah A. Martin

Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, CT 06340
(860) 715-1821



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10959B	SERIAL NO. 10/763,854
	APPLICANT Mark David Fidock	
	FILING DATE 01/22/2004	GROUP 1646

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	2003	0	0	4	9	7	90	03/13/03	Wei, et al.	435	69.1	


FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	1	8	0	9	0	0	08/23/01	International	C07K	14/47		
	WO	0	1	8	7	9	0	0	11/22/01	International	C07K	14/705		
	WO	0	2	8	7	5	1	1	02/21/02	International	C12N	15/12		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
			King, B., et al., <i>Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors</i> , TIPS, Vol. 19: 506-514, 1998											

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 16th day of September, 2004.

By


(Signature of person mailing)
Janice Denison
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark David Fidock :

APPLICATION NO.: 10/763,854 : Examiner: Li, Ruixiang

FILING DATE: 01/22/2004 : Group Art Unit: 1646

TITLE: NOVEL POLYPEPTIDE :

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office copies of PTO-FB-A820 forms, which list the references cited by the applicant(s). These forms were originally submitted with Patent Application No. 10/023,775, from which this case claims priority as a continuation application case. Copies of the cited references are provided for the Examiner's convenience.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: September 15th, 2004

Respectfully submitted,



Deborah A. Martin

Attorney for Applicant(s)

Reg. No. 44,222

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, CT 06340
(860) 715-1821

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> Page 1 of 1				ATTY. DOCKET NO. PC10959AGPR				SERIAL NO. 10/023,775			
APPLICANT Mark David Fidock				FILING DATE December 18, 2001				GROUP 1642			

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	1	3	6	4	7	1	25 May 01	International	C07K	14/00		
	WO	7	1	3	6	4	7	3	25 May 01	International	C07K	14/00		
	WO	7	1	4	9	4	4	7	12 Jul 01	International	C12N	15/12		
	WO	7	1	8	6	7	5	0	13 Sept 01	International	C12N	15/12		
	WO	0	1	8	7	9	3	7	22 Nov 01	International	C07K	14/00		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
		Accession No. AC026756											
		Ayyanathan, K. et. al., "Cloning and Chromosomal Localization of the Human P2Y1 Purinoceptor," <u>Biochemical and Biophysical Research Communications</u> , 218: 783-788, 1996											
		Bhagwat, SS, et. al., "P2 purine and pyrimidine receptors: emerging superfamilies of G-protein-coupled and ligand-gated ion channel receptors," <u>Eur. J. Med. Chem.</u> , 32: 183-193, 1997											
		Flanagan, W., et al., "Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A," <u>Nature</u> , 352: 803-807, 1991											
		Genties, A. J., et. al., "Why are human G-protein-coupled receptors predominantly intronless?" <u>TIG</u> , Vol. 15(2): 47-49, 1999											
		Harden, T. K., et. al., "P2 -Purinergic Receptors: Subtype-Associated Signaling Responses and Structure," <u>Annu. Rev. Pharmacol. Toxicol.</u> 35: 541-579, 1995											
		von Kugelgen, I., et. al., "Molecular pharmacology of P2Y-receptors," <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> , 362: 310-323, 2000											
		Lee, D. K., et. al., "Cloning and characterization of additional members of the G protein-coupled receptor family," <u>Biochimica et Biophysica Acta</u> 1490: 311-323, 2000											
		Lee, D. K., et. al., "Discovery and mapping of ten novel G protein-coupled receptor genes," <u>Gene</u> , 275, 2001, pp. 83-91											
		Marchese, A., et. al., "Cloning of Human Genes Encoding Novel G Protein-Coupled Receptors," <u>Genomics</u> , 23: 609-618, 1994											
		Marchese, A., et. al., "Discovery of Three Novel Orphan G Protein-Coupled Receptors," <u>Genomics</u> , 56: 12-21, 1999											
		O'Dowd, B. F., et. al., "Cloning and chromosomal mapping of four putative novel human G-protein-coupled receptor genes," <u>Gene</u> , 187: 75-81, 1997											
		Palczewski, K., et al., "Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor," <u>Science</u> , 289: 739-745, 2000											
		Parr, C. E., et. al., "Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy," <u>Proc. Natl. Acad. Sci. USA, Medical Sciences</u> , 91: 3275-3279, 1994											

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.